Primary Biliary Cholangitis

Purpose of review Primary biliary cholangitis is a progressive autoimmune cholestatic liver disease more commonly affecting middle-aged women. Here we provide an overview of the diagnosis, clinical presentation, management, and prognosis of patients with PBC. Recent findings Ursodeoxycholic acid (UD...

Full description

Saved in:
Bibliographic Details
Published in:Current treatment options in gastroenterology 2022-06, Vol.20 (3), p.469-483
Main Authors: Scheinberg, Andrew R., Levy, Cynthia
Format: Article
Language:English
Subjects:
Gastroenterology
Medicine
Medicine & Public Health
Pancreas(C Forsmark
Section Editor
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c87z-41ed09a7fda7cea06f6404c1bfc27fb91fa34c18eb5992b3206358b418e92e013
container_end_page 483
container_issue 3
container_start_page 469
container_title Current treatment options in gastroenterology
container_volume 20
creator Scheinberg, Andrew R.
Levy, Cynthia
description Purpose of review Primary biliary cholangitis is a progressive autoimmune cholestatic liver disease more commonly affecting middle-aged women. Here we provide an overview of the diagnosis, clinical presentation, management, and prognosis of patients with PBC. Recent findings Ursodeoxycholic acid (UDCA) remains the first-line treatment for patients with PBC. Incomplete responders are at risk for disease progression. Obeticholic acid (OCA) is a second-line therapy that has shown benefit in patients with PBC who do not respond to or are intolerant of UDCA, and the off-label use of fibrates continues to show promise, including when used in combination with UDCA and OCA. Newer therapies are under investigation. Summary Early diagnosis of PBC combined with the initiation of UDCA remains essential to prevent end-stage liver disease. Risk-stratifying after 1 year of treatment and the need for adjuvant therapy is important to prolong transplant-free survival time.
doi_str_mv 10.1007/s11938-022-00384-z
format article
fullrecord <record><control><sourceid>crossref_sprin</sourceid><recordid>TN_cdi_crossref_primary_10_1007_s11938_022_00384_z</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1007_s11938_022_00384_z</sourcerecordid><originalsourceid>FETCH-LOGICAL-c87z-41ed09a7fda7cea06f6404c1bfc27fb91fa34c18eb5992b3206358b418e92e013</originalsourceid><addsrcrecordid>eNp9jzFPwzAQhS0EEqXwB2DhDxjOPie2R4igVKpUhg5slu3aJVVIkA0D-fW4hIGJ6d093Tu9j5BLBjcMQN5mxjQqCpxTAFSCjkdkxioUFEG_HP-ZT8lZznsAXqHSM3L1nNo3m76u79uuPWjzOnS237UfbT4nJ9F2OVz86pxsHh82zRNdrRfL5m5FvZIjFSxsQVsZt1b6YKGOtQDhmYuey-g0ixbLqoKrtOYOOdRYKSeKo3kAhnPCp7c-DTmnEM371MkwMAc6M9GZQmd-6MxYQjiFcjnudyGZ_fCZ-lLzv9Q3cIdShw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Primary Biliary Cholangitis</title><source>Springer Nature</source><creator>Scheinberg, Andrew R. ; Levy, Cynthia</creator><creatorcontrib>Scheinberg, Andrew R. ; Levy, Cynthia</creatorcontrib><description>Purpose of review Primary biliary cholangitis is a progressive autoimmune cholestatic liver disease more commonly affecting middle-aged women. Here we provide an overview of the diagnosis, clinical presentation, management, and prognosis of patients with PBC. Recent findings Ursodeoxycholic acid (UDCA) remains the first-line treatment for patients with PBC. Incomplete responders are at risk for disease progression. Obeticholic acid (OCA) is a second-line therapy that has shown benefit in patients with PBC who do not respond to or are intolerant of UDCA, and the off-label use of fibrates continues to show promise, including when used in combination with UDCA and OCA. Newer therapies are under investigation. Summary Early diagnosis of PBC combined with the initiation of UDCA remains essential to prevent end-stage liver disease. Risk-stratifying after 1 year of treatment and the need for adjuvant therapy is important to prolong transplant-free survival time.</description><identifier>ISSN: 1534-309X</identifier><identifier>EISSN: 1534-309X</identifier><identifier>DOI: 10.1007/s11938-022-00384-z</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Gastroenterology ; Medicine ; Medicine &amp; Public Health ; Pancreas(C Forsmark ; Section Editor</subject><ispartof>Current treatment options in gastroenterology, 2022-06, Vol.20 (3), p.469-483</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c87z-41ed09a7fda7cea06f6404c1bfc27fb91fa34c18eb5992b3206358b418e92e013</cites><orcidid>0000-0001-5498-6037</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids></links><search><creatorcontrib>Scheinberg, Andrew R.</creatorcontrib><creatorcontrib>Levy, Cynthia</creatorcontrib><title>Primary Biliary Cholangitis</title><title>Current treatment options in gastroenterology</title><addtitle>Curr Treat Options Gastro</addtitle><description>Purpose of review Primary biliary cholangitis is a progressive autoimmune cholestatic liver disease more commonly affecting middle-aged women. Here we provide an overview of the diagnosis, clinical presentation, management, and prognosis of patients with PBC. Recent findings Ursodeoxycholic acid (UDCA) remains the first-line treatment for patients with PBC. Incomplete responders are at risk for disease progression. Obeticholic acid (OCA) is a second-line therapy that has shown benefit in patients with PBC who do not respond to or are intolerant of UDCA, and the off-label use of fibrates continues to show promise, including when used in combination with UDCA and OCA. Newer therapies are under investigation. Summary Early diagnosis of PBC combined with the initiation of UDCA remains essential to prevent end-stage liver disease. Risk-stratifying after 1 year of treatment and the need for adjuvant therapy is important to prolong transplant-free survival time.</description><subject>Gastroenterology</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Pancreas(C Forsmark</subject><subject>Section Editor</subject><issn>1534-309X</issn><issn>1534-309X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9jzFPwzAQhS0EEqXwB2DhDxjOPie2R4igVKpUhg5slu3aJVVIkA0D-fW4hIGJ6d093Tu9j5BLBjcMQN5mxjQqCpxTAFSCjkdkxioUFEG_HP-ZT8lZznsAXqHSM3L1nNo3m76u79uuPWjzOnS237UfbT4nJ9F2OVz86pxsHh82zRNdrRfL5m5FvZIjFSxsQVsZt1b6YKGOtQDhmYuey-g0ixbLqoKrtOYOOdRYKSeKo3kAhnPCp7c-DTmnEM371MkwMAc6M9GZQmd-6MxYQjiFcjnudyGZ_fCZ-lLzv9Q3cIdShw</recordid><startdate>20220621</startdate><enddate>20220621</enddate><creator>Scheinberg, Andrew R.</creator><creator>Levy, Cynthia</creator><general>Springer US</general><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0001-5498-6037</orcidid></search><sort><creationdate>20220621</creationdate><title>Primary Biliary Cholangitis</title><author>Scheinberg, Andrew R. ; Levy, Cynthia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c87z-41ed09a7fda7cea06f6404c1bfc27fb91fa34c18eb5992b3206358b418e92e013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Gastroenterology</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Pancreas(C Forsmark</topic><topic>Section Editor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scheinberg, Andrew R.</creatorcontrib><creatorcontrib>Levy, Cynthia</creatorcontrib><collection>CrossRef</collection><jtitle>Current treatment options in gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scheinberg, Andrew R.</au><au>Levy, Cynthia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Primary Biliary Cholangitis</atitle><jtitle>Current treatment options in gastroenterology</jtitle><stitle>Curr Treat Options Gastro</stitle><date>2022-06-21</date><risdate>2022</risdate><volume>20</volume><issue>3</issue><spage>469</spage><epage>483</epage><pages>469-483</pages><issn>1534-309X</issn><eissn>1534-309X</eissn><abstract>Purpose of review Primary biliary cholangitis is a progressive autoimmune cholestatic liver disease more commonly affecting middle-aged women. Here we provide an overview of the diagnosis, clinical presentation, management, and prognosis of patients with PBC. Recent findings Ursodeoxycholic acid (UDCA) remains the first-line treatment for patients with PBC. Incomplete responders are at risk for disease progression. Obeticholic acid (OCA) is a second-line therapy that has shown benefit in patients with PBC who do not respond to or are intolerant of UDCA, and the off-label use of fibrates continues to show promise, including when used in combination with UDCA and OCA. Newer therapies are under investigation. Summary Early diagnosis of PBC combined with the initiation of UDCA remains essential to prevent end-stage liver disease. Risk-stratifying after 1 year of treatment and the need for adjuvant therapy is important to prolong transplant-free survival time.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s11938-022-00384-z</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-5498-6037</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1534-309X
ispartof Current treatment options in gastroenterology, 2022-06, Vol.20 (3), p.469-483
issn 1534-309X
1534-309X
language eng
recordid cdi_crossref_primary_10_1007_s11938_022_00384_z
source Springer Nature
subjects Gastroenterology
Medicine
Medicine & Public Health
Pancreas(C Forsmark
Section Editor
title Primary Biliary Cholangitis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T22%3A56%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref_sprin&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Primary%20Biliary%20Cholangitis&rft.jtitle=Current%20treatment%20options%20in%20gastroenterology&rft.au=Scheinberg,%20Andrew%20R.&rft.date=2022-06-21&rft.volume=20&rft.issue=3&rft.spage=469&rft.epage=483&rft.pages=469-483&rft.issn=1534-309X&rft.eissn=1534-309X&rft_id=info:doi/10.1007/s11938-022-00384-z&rft_dat=%3Ccrossref_sprin%3E10_1007_s11938_022_00384_z%3C/crossref_sprin%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c87z-41ed09a7fda7cea06f6404c1bfc27fb91fa34c18eb5992b3206358b418e92e013%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true